InnoSer

Xenograft models created by the injection of cancer cells into immune-compromised mice to establish therapeutic proof-of-concept.

Preclinical oncology contract research service utilizing patient-derived xenograft mouse models to evaluate the efficacy of anticancer therapies and recapitulate patient tumor heterogeneity.

Predictive preclinical models reflecting patients' tumor biology, utilizing tumor samples that maintain original genetic and histological characteristics.

Proprietary primary patient tumor samples turned into patient-derived organoids providing meaningful translation of therapeutic responses.

Gold-standard translational approach for modelling solid tumors, emphasizing GI tumors and specifically PDAC.

Double transgenic combined amyloid and tau mouse model expressing human APP[V717I] and human Tau[P301S] under control of the neuron-specific Thy-1 promoter for evaluating multi-target therapeutics in Alzheimer's disease.

Double transgenic mouse model combining APP and Tau[P301L] mutations for Alzheimer’s and tauopathy research.

Early-onset amyloidosis pathology transgenic Alzheimer’s disease model to test therapies targeting Aβ accumulation, neuroinflammation, and cognitive impairment.

Mutations in the PMP22 gene cause several forms of neuropathies such as Charcot-Marie-Tooth Disease Type 1A.

Specialized preclinical rare genetic disease model for Charcot Marie Tooth Disease research.

Progressive, well-characterized Tau pathology mouse model designed for mechanism-driven preclinical efficacy studies.

A homozygous model showing robust Tau pathology from 2.5–3 months and a heterozygous variant for longer-term studies, enabling rapid evaluation of Tau-targeting approaches using Total Tau, pTau181, and NfL.

Research services with several different transgenic tau models recapitulating Tau neurofibrillary tangle pathology.

A well-characterized preclinical research model featuring a heterozygous loss of the STXBP1 gene, designed to study STXBP1 epileptic encephalopathy and evaluate novel targeted therapies.

PrP-driven homozygous transgenic tau mouse model with robust progressive motor phenotype from 3–4 months.

PrP-driven transgenic commercial tau mouse model widely used in preclinical research.

Tau[P301S] recipient model utilizing human- or mouse-derived seeds to model prion-like tau spreading.

PrP-driven homozygous transgenic tau mouse model with robust progressive motor phenotype from 3–4 months.

Specialized disease model service for vanishing white matter leukodystrophy research.

InnoSer offers unique services with an Eif2b4 / Eif2b5 mouse model of vanishing white matter (VWM).

A conditional, renal-specific Pkd1 knock-out ADPKD mouse model used to test the efficacy of novel therapeutics for Polycystic Kidney Disease.

Mouse model leveraging widespread amyloid-beta pathology for robust preclinical efficacy studies of amyloid-lowering therapeutic programs.

Early-onset amyloidosis transgenic APPxPS1 Alzheimer’s disease model for testing efficacy of therapies targeting amyloid-beta accumulation, neuroinflammation, and cognitive impairment.

Specialized preclinical rare genetic disease model for Phelan-McDermid Syndrome research.

Shank3 knockout mouse model service dedicated to Phelan-McDermid syndrome drug discovery.

An in vivo preclinical research model utilizing stereotaxic injection of sonicated recombinant mouse alpha-synuclein pre-formed fibrils (mPFFs) into the dorsal striatum of wild-type C57BL/6J mice to investigate therapeutic efficacy against alpha-synuclein aggregation, spreading, and dopaminergic neurodegeneration.

Alpha-synuclein seeding mouse models utilizing both PD patient-derived brain and recombinant seeds.

Preclinical contract research organization (CRO) services supporting vaccine and mRNA/RNA therapy development with in vivo immunogenicity testing, biodistribution studies, and in vitro immunoassays.

Fee-for-service transgenic alpha-synuclein mouse models for preclinical testing.

InnoSer offers MPTP mouse model, transgenic alpha-synuclein, or seeding alpha-synuclein mouse models using recombinant and/or patient-derived seeds.

A widely used transgenic mouse model overexpressing human A53T mutant alpha-synuclein under the PrP promoter, recapitulating key hallmarks of progressive alpha-synucleinopathy for preclinical efficacy and seeding studies.

Preclinical mouse model used for studying T and B lymphocyte-driven neuroinflammation and immune-mediated demyelination.

Inducible Parkinson's disease model services using MPTP-based approaches.

Patient-derived xenograft and organoid platform combining PDO and PDX models to capture and recapitulate patient variability across various malignancies.

Specialized animal model assays and studies focusing on neuroinflammatory processes and drug evaluation.

Contract research services utilizing various APP transgenic mouse models with amyloid beta plaque deposition and downstream pathological events for preclinical efficacy studies.

Preclinical services featuring an AD brain extract injection model providing a translational model of Tau pathology seeding and spreading.

An overview leaflet providing information on current available oncology models within the InnoSer portfolio to help compare model features and evaluate compound efficacy.

First fully characterized human midbrain organoid platform for Parkinson's disease compound screening.

Preclinical in vitro immunoassay services utilizing rodent and human cell lines or primary cells to evaluate investigational compounds, assess immune cell composition, and conduct initial screening.

Models where cells, tumor fragments or organoids are grafted at the orthotopic site in the primary niche of immune-compromised mice.

Mouse models providing a general impression of the efficacy of immuno-oncology drugs on generalized tumor types.

Extensively validated zQ175 knock-in transgenic Huntington's disease mouse model combined with comprehensive behavioural and molecular phenotyping platforms.

Preclinical mouse model used to study the effects of novel remyelinating compounds, targeting oligodendrocyte precursor cells and neuroprotective strategies.

Diet-induced obesity mouse model for metabolic disease and obesity research.

Preclinical mouse model producing a discrete, anatomically targeted demyelinating lesion via direct stereotaxic injection of lysophosphatidylcholine into CNS white matter.

A preclinical rodent model used for inducing colitis to study therapeutic interventions and immune response mechanisms.

Explore our advanced preclinical ALS mouse models, crucial for preclinical efficacy studies and understanding disease mechanisms.

A preclinical rodent disease model characterized by a spontaneous spasticity-associated mutation resulting in early-onset hypertonia, used for studying novel interventions for muscular spasticity.

Transgenic ALS mouse model available within the InnoSer portfolio for evaluating compound efficacy.

InnoSer offers APP transgenic mice as well as transgenic Tau and Tau seeding models using recombinant and/or patient-derived seeds.

Thy1_Tau[P301L] transgenic mouse model exhibiting motor deficits and tau pathology.

Surgical and behavioral mouse model for spinal cord injury research and recovery assessments.

Preclinical efficacy and behavioral study services using the mdx (B10.mdx) mouse model for investigating targeted Duchenne Muscular Dystrophy therapies.

Murine colorectal carcinoma MC38 cell line model available as both subcutaneous and orthotopic configurations.

A chemically induced mouse model utilizing DSS in drinking water to simulate acute colitis, epithelial damage, and intestinal inflammation.

Murine breast cancer 4T1 cell line model available as a subcutaneous model followed via calipers or an orthotopic (4T1-luc) model followed via bioluminescent imaging.

Test novel investigational therapy's effect on glycemic control and glucose tolerance using Type 1 diabetes mouse models.

Rodent disease models specifically configured for Type 1 Diabetes research and therapeutic testing.

Advanced preclinical screening service enabling the testing of multiple lead drug candidates on patient-derived organoid cancer models using robotics, label-free live-cell imaging, and automated image and data analytics.

Murine renal cell carcinoma Renca cell line model available in subcutaneous and orthotopic configurations for longitudinal imaging and quantification.

Mouse model services designed for Duchenne Muscular Dystrophy preclinical efficacy testing.

Humanized mouse models represent one of the most translationally relevant immuno-oncology tools for preclinical evaluation.

InnoSer offers oncology CRO services using cancer-associated tumor and microenvironment-associated cell lines (human and rodent).

Murine pancreatic cancer PanO2 cell line model established by subcutaneous injection into the left flank of C57BL/6 mice.

In vitro neurology assay services supporting neuroscience drug discovery and mechanism of action studies.

A translationally relevant preclinical research model (Ube3a mE113X/p+, MGI:5911277 variant) for evaluating novel therapeutics for Angelman Syndrome, featuring standardized behavioral test batteries and biomarker analyses.

Mouse models with intact immune systems to study initial efficacy data in pancreatic cancer research.

In vivo model for evaluating the efficacy of potential immunomodulatory or immunosuppressive compounds to modulate cellular immune responses.

A well-characterized and translationally relevant in vivo Fmr1 KO mouse model used for preclinical research, efficacy studies, and evaluating therapeutic interventions for Fragile X Syndrome (FXS).

Inflammatory Bowel Disease (IBD) mouse models and preclinical testing services to evaluate efficacy and improve gut health.

Preclinical mouse model study induced via Angiotensin II for hypertension and cardiovascular research.

Thy1-driven double transgenic commercial Alzheimer's disease mouse model with intermediate progression, suitable for treatment paradigm studies.

Transgenic mouse model services tailored for Huntington’s disease preclinical investigations.

Specialized preclinical research services using the C3-PMP22 mouse model of Charcot-Marie-Tooth Disease Type 1A (CMT1A) for testing the efficacy of new treatments.

Models capable of exhibiting the metastatic cascade with fluorescent tagging for real-time tracking.

Multiplex biomarker quantification and electrochemiluminescence immunoassay services for preclinical drug development and pharmacodynamic endpoint measurement.

A well-characterized, translationally relevant preclinical knock-in mouse model carrying a β-geo cassette in the Kmt2d locus, used for evaluating novel therapeutics and epigenetic approaches for Kabuki Syndrome Type 1.

An acute psoriasis mouse model created by intradermal ear injections of recombinant IL-23, leading to acute skin inflammation and serving as a preclinical testing service for psoriasis treatments.

A customized preclinical acceleration program designed to help startups and academic spinoffs progress drug candidates from concept to development with flexible support, infrastructure, and expertise.

A translational license-free mouse model engineered with deletion of exon 4 through 22 of the Shank3 mouse gene for studying Phelan-McDermid Syndrome and related SHANK3 neurodevelopmental disorders.

Genetically modified mouse model for type 2 diabetes mellitus and metabolic research.

Fast, flexible non-GLP studies to de-risk your lead compound before committing to GLP testing, including dose range-finding, tolerability, and translational relevance.

Rodent model studies focused on age-related physiological changes and therapeutic interventions.

Test novel compounds targeting Multiple Sclerosis with the support of our services in de- and re-myelinating multiple sclerosis mouse models.

Surgical mouse model of heart failure utilized for evaluating cardiovascular therapeutics and heart failure progression.

PrP_Tau[P301S] recipient model utilizing human, mouse, or recombinant seeds to model prion-like tau spreading.

Preclinical compound screening service using a conditional knock-out of Pkd1 in mice for Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Commercially available cancer cell lines for early drug screening, applied as tumor models in 2D or 3D matrices as spheroids.

Rat model designed to study cardiac dysfunction associated with diabetes.

Genetically altered mouse model service for investigating Fragile X Syndrome mechanisms and treatments.

Knock-in Alzheimer's disease mouse model using endogenous App regulatory elements with early pathology onset around 2–4 months.

Non-GLP toxicology, biocompatibility, single-dose toxicity, and repeated-dose toxicity testing services.

Overview leaflet detailing current cardio-metabolic models available within the InnoSer portfolio, including model comparison tables and key endpoints for compound efficacy evaluation.

Comprehensive hit to lead drug development services combining in vitro and in vivo methods to screen analogues and optimize compound properties.

Specialized preclinical rare genetic disease model for Angelman Syndrome research.

Specialized preclinical rare genetic disease model for Tuberous Sclerosis Complex research.

Specialized preclinical rare genetic disease model for 22q11.2 deletion syndrome research.

Specialized preclinical rare genetic disease model for Kabuki Syndrome research.

Dose-response and regimen evaluation, PK/PD assessments, non-GLP toxicity and tolerability profiling, MTD studies, and formulation assessment support.

Investigate relevant compounds to promote increased human longevity and healthy ageing thanks to our experience with InnoSer’s naturally aged mouse model.

Cell-based assays, organoid high-throughput screening, mechanism-of-action studies, early in vivo proof-of-concept, and biomarker analysis.

A clinically validated ultrasound-mediated blood-brain barrier (BBB) disruption platform using low-intensity pulsed ultrasound (LIPU) with intravenous microbubbles to enhance drug delivery to the brain for preclinical and clinical CNS therapeutics development.